Trial Profile
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Relugolix (Primary)
- Indications Pain; Uterine leiomyoma
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 06 Oct 2019 Safety and efficacy results published in the Fertility and Sterility.
- 13 Feb 2018 According to a Myovant Sciences media release, Takeda plans to submit the results from the trial to regulatory authorities in Japan for marketing authorization of relugolix for the treatment of uterine fibroids.
- 09 Nov 2017 Results published in a Myovant Sciences media release.